Dark

VKTX
Viking Therapeutics, Inc
stock NASDAQ

Market Open

Jun 16, 2025 11:25:56 AM EDT

26.47USD+1.476%(+0.39)1,238,235

26.44Bid 26.49Ask 0.05Spread

Pre-market

Jun 16, 2025 9:25:30 AM EDT

26.45USD+1.419%(+0.37)35,223

After-hours

Jun 13, 2025 4:57:30 PM EDT

26.17USD+0.345%(+0.09)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 26, 2022

10:25AM EST Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. (Viking or the Company) (NASDAQ:VKTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Jan 24, 2022

07:16AM EST Biopharmaceutical company Viking Therapeutics, Inc. (VKTX) announced Monday that its Phase 1b clinical trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD) has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). RTTNews

07:09AM EST Viking Announces Clinical Hold On Phase 1b Trial Of VK0214 In Patients With X-ALD RTTNews

07:08AM EST Viking Therapeutics Announces Clinical Hold On Phase 1b Trial Of VK0214 In Patients With X-ALD Benzinga

07:02AM EST Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in PR Newswire

Jan 10, 2022

07:12AM EST Viking Therapeutics Announces Initiation Of Phase 1 Clinical Trial Of VK2735 RTTNews

07:05AM EST Viking Therapeutics Announces Initiation Of Phase 1 Clinical Trial Of VK2735, Company's Lead Dual GLP-1/GIP Receptor Agonist Benzinga

07:02AM EST Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK2735, PR Newswire

Jan 3, 2022

07:30AM EST Viking Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference PR Newswire

Dec 21, 2021

08:21AM EST Viking Therapeutics Granted U.S. Patent #11,202,789 'Method of treating glycogen storage disease' Benzinga

Nov 9, 2021

04:06PM EST Viking Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference PR Newswire

Nov 3, 2021

05:39PM EDT Viking Therapeutics Q3 EPS $(0.17) Beats $(0.21) Estimate Benzinga

04:06PM EDT Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides PR Newswire

09:19AM EDT The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering Benzinga

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

Nov 1, 2021

07:55AM EDT Viking Therapeutics Reports Promising Preclinical Data On RTTNews

07:13AM EDT Viking : Dual-Receptor Agonists GLP-1/GIP Show Potent Weight Loss &Improve Metabolic Profile In Diet-Induced Obese Mice RTTNews

07:07AM EDT Viking Therapeutics Presents Preclinical Data On Novel Dual GLP-1/GIP Agonists At ObesityWeek 2021 Benzinga

07:03AM EDT Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists PR Newswire

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 27, 2021

04:06PM EDT Viking Therapeutics to Report Financial Results for Third Quarter 2021 on PR Newswire

Oct 25, 2021

07:17AM EDT Viking Therapeutics To Present Preclinical Data On Novel Dual GLP-1/GIP Agonists At ObesityWeek 2021 Benzinga

07:14AM EDT Sterling Check Appoints Judah Sokel As VP Of Investor Relations RTTNews

07:06AM EDT Viking Therapeutics to Present Preclinical Data on Novel Dual GLP-1/GIP PR Newswire

Oct 5, 2021

04:08PM EDT Viking Therapeutics To Present At H.C. Wainwright's 5th Annual NASH Investor Conference Oct. 12 Benzinga

04:05PM EDT Viking Therapeutics to Present at H.C. Wainwright's 5th Annual NASH Investor PR Newswire

Sep 2, 2021

04:05PM EDT Viking Therapeutics to Participate in Upcoming Investor Conferences PR Newswire

Jul 29, 2021

08:58AM EDT Raymond James Maintains Outperform on Viking Therapeutics, Raises Price Target to $13 Benzinga

Jul 28, 2021

05:27PM EDT Viking Therapeutics S-3 Shows Registration For $600M Mixed Securities Shelf Offering Benzinga

04:47PM EDT Viking Therapeutics Q2 EPS $(0.20), Inline Benzinga

04:06PM EDT Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides PR Newswire

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

04:27AM EDT Earnings Scheduled For July 28, 2021 Benzinga

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 22, 2021

12:41PM EDT Viking Therapeutics ClinicalTrials.gov Study Record Detail For Co.'s 'A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN', Study Is Recruiting Benzinga

Jul 21, 2021

04:05PM EDT Viking Therapeutics to Report Financial Results for Second Quarter 2021 on July PR Newswire

Jun 30, 2021

11:24AM EDT UPDATE: Roth Capital On Viking Therapeutics Buy Rating: Firm Highlights Continued Clinical Development Of VK0214 Treatment For X-ALD With Promising Phase 1a Data Leading Continuation Into Phase 1b Trials Attempting To Duplicate Results Benzinga

11:24AM EDT Roth Capital Maintains Buy Rating On Viking Therapeutics, Price Target $20. Benzinga

Jun 24, 2021

07:13AM EDT Viking Therapeutics Begins Phase 1b Clinical Trial Of VK0214 RTTNews

07:10AM EDT Viking Therapeutics Initiates Phase 1b Clinical Trial Of VK0214 In Patients With X-ALD RTTNews

07:09AM EDT Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD Benzinga

07:05AM EDT Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 PR Newswire

Jun 17, 2021

08:23AM EDT Viking Therapeutics' VK0214 Shows Encouraging Safety, Tolerability Profile In Healthy Volunteers Benzinga

07:09AM EDT Viking Therapeutics Announces Results From Phase 1 Clinical Trial Of Novel Oral Thyroid Receptor Beta Agonist VK0214 RTTNews

07:07AM EDT Viking Therapeutics Announces Results From Phase 1 Clinical Trial Of Novel Oral Thyroid Receptor Beta Agonist VK0214; Says VK0214 'demonstrated encouraging safety and tolerability, as well as a predictable pharmacokinetic (PK) profile' Benzinga

07:05AM EDT Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral PR Newswire

Jun 10, 2021

04:05PM EDT Viking Therapeutics to Participate in Upcoming Investor Conferences PR Newswire

May 27, 2021

08:24AM EDT The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs Benzinga

May 26, 2021

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

May 25, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021 Benzinga

08:01AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

07:01AM EDT Raymond James Downgrades Viking Therapeutics to Outperform, Lowers Price Target to $12 Benzinga

Apr 29, 2021

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

Apr 28, 2021

04:33PM EDT Viking Therapeutics Q1 EPS $(0.19) Misses $(0.17) Estimate Benzinga

04:06PM EDT Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides PR Newswire

07:26AM EDT The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping Benzinga

04:15AM EDT Earnings Scheduled For April 28, 2021 Benzinga

Apr 24, 2021

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

Apr 21, 2021

04:06PM EDT Viking Therapeutics to Report Financial Results for First Quarter 2021 on April PR Newswire

Apr 7, 2021

04:05PM EDT Viking Therapeutics to Present at 20th Annual Needham Virtual Healthcare PR Newswire

Apr 6, 2021

09:07AM EDT Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly Benzinga

Mar 4, 2021

04:31PM EST Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire

Feb 18, 2021

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

Feb 17, 2021

04:16PM EST Viking Therapeutics Q4 EPS $(0.15), Inline Benzinga

04:05PM EST Viking Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results PR Newswire

04:34AM EST Earnings Scheduled For February 17, 2021 Benzinga

Feb 10, 2021

04:05PM EST Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End PR Newswire

Feb 5, 2021

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

Jan 28, 2021

08:03AM EST The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO Benzinga

Jan 6, 2021

04:08PM EST Viking Therapeutics Announces Greg Zante Promoted To Chief Financial Officer And Marianne Mancini Promoted To Chief Operating Officer Benzinga

04:05PM EST Viking Therapeutics Announces Senior Management Team Appointments PR Newswire

Jan 5, 2021

04:05PM EST Viking Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference PR Newswire

Nov 10, 2020

04:06PM EST Viking Therapeutics to Present at Stifel Healthcare Conference 2020 PR Newswire

Oct 29, 2020

08:54AM EDT Raymond James Maintains Strong Buy on Viking Therapeutics, Raises Price Target to $27 Benzinga

Oct 28, 2020

04:13PM EDT Viking Therapeutics Q3 EPS $(0.13) Beats $(0.15) Estimate Benzinga

04:06PM EDT Viking Therapeutics Reports Third Quarter 2020 Financial Results and Provides PR Newswire

Oct 21, 2020

04:05PM EDT Viking Therapeutics to Report Financial Results for Third Quarter 2020 on PR Newswire

Sep 9, 2020

07:10AM EDT Viking Therapeutics Says Commences Phase 1 Trial Of VK0214 As Potential Treatment For X-linked Adrenoleukodystrophy RTTNews

07:10AM EDT Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214 Benzinga

Sep 2, 2020

04:31PM EDT Viking Therapeutics to Participate in Upcoming Investor Conferences PR Newswire

Aug 31, 2020

08:50AM EDT 10 Biggest Price Target Changes For Monday Benzinga

05:07AM EDT Chardan Capital Maintains Buy on Viking Therapeutics, Raises Price Target to $20 Benzinga

Aug 28, 2020

09:15AM EDT HC Wainwright & Co. Maintains Buy on Viking Therapeutics, Raises Price Target to $21 Benzinga

06:05AM EDT Viking Therapeutics Highlights Presentation Of New Data From Phase 2 Study Of VK2809 In Patients With Non-Alcoholic Fatty Liver Disease And Elevated LDL-Cholesterol At The Digital International Liver Congress 2020 Benzinga

Aug 20, 2020

07:40AM EDT Viking To Present Data From Phase2 Study Of VK2809 In Patients With Non-Alcoholic Fatty Liver Disease&Elevated LDL-C RTTNews

07:33AM EDT Viking Therapeutics To Present New Data From Phase 2 Study Of VK809 In Patients With Non-Alcoholic Fatty Liver Disease And Elevated LDL-Cholesterol Benzinga

07:30AM EDT Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress(tm) 2020 PR Newswire

Jul 29, 2020

04:12PM EDT Viking Therapeutics Q2 EPS $(0.13) Beats $(0.14) Estimate Benzinga

04:06PM EDT Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides PR Newswire

04:04AM EDT Earnings Scheduled For July 29, 2020 Benzinga

Jul 28, 2020

04:06PM EDT Viking Therapeutics to Participate in Upcoming Investor Conferences PR Newswire

Jul 22, 2020

04:05PM EDT Viking Therapeutics to Report Financial Results for Second Quarter 2020 on July PR Newswire